Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 30 06 2023
revised: 26 07 2023
accepted: 27 07 2023
medline: 1 9 2023
pubmed: 31 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

Melanoma, an aggressive skin cancer, poses a significant threat to patients' lives, with lower limbs and hips being among the most affected regions. Epidemiology and survival outcomes of patients with melanoma in the lower extremities were investigated and compared to other sites to better understand tumoral behavior and identify predictors of decreased survival. The Surveillance, Epidemiology, and End Results (SEER) database was used to search for all skin melanoma cases between 2000 and 2019. Demographic, pathological, and therapeutic factors were compared between affected regions. Overall and disease specific survival were calculated and compared among subgroups. A multivariable analysis was conducted to identify independent prognostic factors. A total of 50,109 patients were diagnosed with melanoma in lower limbs and hips, while 224,121 patients had melanomas in other areas. More women (70.8%) and younger people (mean 55.2 years, SD 16.5) were affected with lower extremities melanoma, with better survival rates than other skin regions. Factors associated with better survival included female sex, younger age, horizontal growth pattern melanomas, and surgery with <1 cm margins. Melanoma affecting lower extremities is commonly diagnosed in young females. Prognosis depends on age, stage at diagnosis, and histologic subtype, but remains better compared to other locations.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Melanoma, an aggressive skin cancer, poses a significant threat to patients' lives, with lower limbs and hips being among the most affected regions. Epidemiology and survival outcomes of patients with melanoma in the lower extremities were investigated and compared to other sites to better understand tumoral behavior and identify predictors of decreased survival.
PATIENTS AND METHODS METHODS
The Surveillance, Epidemiology, and End Results (SEER) database was used to search for all skin melanoma cases between 2000 and 2019. Demographic, pathological, and therapeutic factors were compared between affected regions. Overall and disease specific survival were calculated and compared among subgroups. A multivariable analysis was conducted to identify independent prognostic factors.
RESULTS RESULTS
A total of 50,109 patients were diagnosed with melanoma in lower limbs and hips, while 224,121 patients had melanomas in other areas. More women (70.8%) and younger people (mean 55.2 years, SD 16.5) were affected with lower extremities melanoma, with better survival rates than other skin regions. Factors associated with better survival included female sex, younger age, horizontal growth pattern melanomas, and surgery with <1 cm margins.
CONCLUSION CONCLUSIONS
Melanoma affecting lower extremities is commonly diagnosed in young females. Prognosis depends on age, stage at diagnosis, and histologic subtype, but remains better compared to other locations.

Identifiants

pubmed: 37648311
pii: 43/9/4105
doi: 10.21873/anticanres.16600
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4105-4113

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Solange N Walz (SN)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.

Jérôme Martineau (J)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.

Matteo Scampa (M)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.

Srinivas Madduri (S)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Bioengineering and Neuroregeneration Laboratory, Department of Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.

Daniel F Kalbermatten (DF)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.

Carlo M Oranges (CM)

Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, Geneva, Switzerland; carlo.oranges@hcuge.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH